Eton Pharmaceuticals Q3 revenue jumps 158% on portfolio sales growth; raises 2026 outlook
ETON•Eton Pharmaceuticals' third-quarter revenue rose 158% year over year to a record $57.9 million. The company raised its 2026 revenue outlook to more than $175 million and adjusted EBITDA margin outlook to at least 40%.
1. Record quarterly revenue
Eton Pharmaceuticals reported third-quarter revenue of $57.9 million, up 158% year over year. Adjusted EPS was $0.50, adjusted EBITDA margin was 49%, and net income was $35.25 million.
2. Higher 2026 outlook
The company raised its 2026 revenue guidance to more than $175 million, from more than $145 million, and its adjusted EBITDA margin outlook to at least 40%, from 35%. It expects full-year 2026 adjusted gross margin to exceed 70%. Revenue growth was driven by the addition of HEMANGEOL sales, higher sales across several products, record active patient counts for key products and a favorable product mix.
